

Antibiogram Data from 2024 Isolates

Niaz Banaei, M.D., Director of Clinical Microbiology Laboratory
William Rotunno, CLS, Laboratory Reference Technologist, Antibiotics
Farnaz Foroughi, CLS, Laboratory Reference Technologist, AFB
Laleh Ghafghaichi, CLS, Laboratory Reference Technologist, Mycology

Values expressed are % susceptible R = intrinsic resistance “-” = data not available

Gram Negative Rods		No. of Isolates (a)	Penicillins		Cephalosporins and Lactams					Carbapenems		Aminoglyc's			Others		Urines Only	
			Ampicillin (\$)	Piper/Tazobactam (\$\$)	Cefuroxime (IV) (\$)	Ceftriaxone (\$)	Ceftazidime (\$)	Cefepime (b) (\$)	Aztreonam (\$\$\$)	Ertapenem (\$\$\$)	Meropenem (\$\$)	Amikacin (\$\$\$)	Gentamicin (\$\$\$)	Tobramycin (\$\$\$)	Ciprofloxacin (\$)	Trimethoprim/sulfa (\$)	Cefazolin (c) (\$) Predicts 1st gen cephem	Nitrofurantoin (c) (\$\$\$)
Achromobacter xylosoxidans		22(d,e)	R	82	R	R	77	0	0	R	96	18	5	14	18	100	R	-
Acinetobacter baumannii complex		14(d,e)	R	-	R	R	79	71	R	R	86	79	71	71	86	86	R	-
Citrobacter freundii complex		26(d,e)	R	61	R	58	61	-	-	100	100	100	100	100	96	92	R	100
Enterobacter cloacae complex		53	R	59	R	51	56	72 / 24	60	81	100	100	100	100	88	90	R	50
Escherichia coli		520	46	94	64	87	95	77 / 7	71	99	99	98	89	89	79	68	81	97
Klebsiella aerogenes		26(d)	R	71	R	61	65	62 / 0	62	77	85	91	100	100	96	79	R	8
Klebsiella oxytoca		45	R	91	69	87	91	79 / 0	79	100	100	100	98	98	98	84	59	97
Klebsiella pneumoniae		100	R	89	85	84	92	85 / 0	95	100	100	99	91	89	82	73	85	21
Morganella morganii		13(d)	R	-	R	85	77	100 / 0	-	100	-	-	77	69	69	69	R	R
Proteus mirabilis		43	84	100	-	95	98	-	100	100	100	100	95	95	91	84	88	R
Pseudomonas aeruginosa		126	R	91	C/T 99		94	93	82	R	94	100(c)	-	100	90	R	R	R
Pseudomonas aeruginosa (CF-mucoid) (f)		26(d,e)	R	92	C/T 92		92	85	76	Imp 84	89	-	-	89	65	R	R	R
Pseudomonas aeruginosa (CF-non-mucoid) (f)		27(d)	R	89	C/T 100		96	96	93	Imp 89	93	-	-	85	93	R	R	R
Salmonella spp.		28(d)	86	-	R	96	-	-	-	-	-	R	R	R	39	86	R	-
Serratia marcescens		37	R	100	R	92	97	100 / 0	100	100	100	100	100	87	95	100	R	R
Stenotrophomonas maltophilia		53	R	R	R	R	-	-	R	R	R	R	R	Levo 93	98		R	-

(a) First isolate from each patient was included.

(b) Shows susceptible / susceptible-dose dependent. Not routinely tested on urine and blood Enterobacterales isolates.

(c) Urine only.

(d) Data from isolate totals <30 may be statistically unreliable.

(e) Includes isolates from 2023.

(f) Cystic fibrosis patient isolates tested by disk diffusion.

A/S = Ampicillin/Sulbactam; C/T = Ceftolozane/Tazobactam;
Imp = Imipenem; Levo = Levofloxacin

Values expressed are % susceptible R = intrinsic resistance "-" = data not available

Gram Positive Cocci

Gram Positive Cocci	Number of Isolates (a)	Beta-Lactams								Others								
		Oxacillin/Nafcillin (\$\$)	Penicillin or Ampicillin (\$)			1st Generation cephem (\$)	Cefuroxime (\$)	Ceftriaxone (\$)	Meropenem (\$\$\$)	Levofloxacin (\$\$)	Ciprofloxacin (b) (\$)	Clindamycin (c) (\$)	Erythromycin (\$\$\$)	Nitrofurantoin (b) (\$\$\$)	Trimethoprim/sulfa (\$)	Vancomycin (\$\$\$)	Tetracycline (\$\$)	Linezolid (\$\$\$\$)
			%S	%I	%R													
Staphylococcus aureus	485	86	(d)	-	-	86	-	-	-	-	-	78	70	-	100	100	-	-
MRSA only	65	0	0	-	-	0	-	-	-	-	-	62	26	-	100	100	89	100
Staphylococcus lugdunensis	4(e)	100	(d)	-	-	100	-	-	-	-	-	75	100	-	100	100	-	-
Staphylococcus spp., Coagulase-negative	53	28	(d)	-	-	28	-	-	-	-	-	58	29	-	64	100	-	-
Enterococcus faecium	13(e)	-	46	-	54	R	R	R	-	-	50	R	-	29	R	100	-	100
Enterococcus faecalis	26(e)	-	100	-	0	R	R	R	-	-	-	R	-	-	R	100	-	-
Streptococcus group B	22	-	100	0	0	-	-	-	-	-	-	41	-	-	-	-	-	-
Viridans group Streptococci	33	-	70	16	11	-	-	97	-	85	-	79	49	-	-	100	-	-
Streptococcus pneumoniae	26(e)	-	65(f)	-	35	-	92	96(g)	92	-	-	81	73	-	65	100	Doxycycline 67	

Drug cost: Please choose the appropriate antibiotic based on best spectrum of coverage and lowest cost. Costs are reflective of 1 day of therapy based on adult dosing and include drug levels and reformulations.

\$ = \$0-20
 \$\$ = \$20-50
 \$\$\$ = \$50-100
 \$\$\$\$ = >\$100

(a) First isolate from each patient was included. (b) Urine only. (c) Testing for inducible clindamycin resistance performed on all Staphylococci, group B Strep, and S. pneumoniae. (d) Penicillin sensitivity confirmed by request. (e) Data from isolate totals <30 may be statistically unreliable. (f) Based on meningitis interpretive criteria (more conservative). Nonmeningitis interpretation is 96%. (g) Ceftriaxone uses the meningitis interpretive criteria (more conservative).

Candida

Percent Susceptible By Broth Microdilution (YeastOne, Trek Diagnostics)	No. Tested	Amphotericin B (a) (\$\$\$\$)	Fluconazole (b) (\$)	Voriconazole (\$\$\$\$)	Caspofungin (c) (\$\$)
Candida albicans	17(d,e)	100	100/0	100	94
Candida glabrata	6(d,e)	100	0/100	-	100
Candida parapsilosis	14(d,e)	100	100/0	100	100
Other Candida species	4(d,e)	100	(f)	75	50

(a) Suggested Ampho Resistant breakpoint MIC > or = 2 mcg/ml. (b) Shows susceptible / susceptible-dose dependent. (c) Consult Peds ID if Caspofungin being considered for treatment. (d) Data from isolate totals <30 may be statistically unreliable. (e) Includes isolates from 2023. (f) Species other than C. krusei are 100% susceptible; C. krusei is intrinsically resistant to fluconazole.

Haemophilus influenzae

For infections with beta-lactamase producing H. influenzae: cefuroxime, ceftriaxone, trimethoprim/sulfamethoxazole, amoxicillin/clavulanate, or azithromycin is recommended. Ceftriaxone is drug of choice for CNS infections. At LPCH, 63% (n=30) of H. influenzae are ampicillin susceptible.